•  
  •  
  •  
  •  

2023-11-30 10:39:52

  • Home
  • Commodities
  • Industry News
  • IPO
  • Mutual Funds
  • Others
  • Research
  • Watch List
Latest News
  • IREDA makes stellar debut, closes at 87.50% premium to IPO price
  • Foot Locker announces strategic partnership with Metro Brands Ltd and Nykaa Fashion
  • Mahindra Logistics to acquire majority stake in Whizzard
  • R Systems International Ltd honored as one of the 'Value Creators' in Dun & Bradstreet's 'India's Top 500 Value Creators 2023'
  • Ujjivan Small Finance Bank partners with Water.org to offer Water, Sanitation and Hygiene loans

Keywords Selected:  INE044A01036

Stock Report

  • Nidlegy™ Phase III PIVOTAL trial meets the study's primary objective
  • Sun Pharma announces US FDA Filing Acceptance of New Drug Application For Deuruxolitinib
  • Sun Pharma Canada Launches PRWINLEVI® - clascoterone cream 1% w/w, a Novel Topical Treatment for Acne
  • LIC dilutes stake in Sun Pharma
  • Sun Pharma and Pharmazz Inc. enter into licensing agreement for introducing Tyvalzi™ in India
  • Sun Pharmaceuticals Industries Ltd recommends final dividend of Rs. 4
  • Sun Pharmaceutical Industries Ltd - Deuruxolitinib - CTP-543 - Clinical Program Update
  • Sun Pharma launches CEQUA®, a novel therapy for Dry Eye Disease in India
  • Sun Pharmaceutical Industries Limited updates on Mohali facility
  • Sun Pharma to acquire 60% stake in Vivaldis Health and Foods Pvt Ltd
  • Osteoarthritis Candidate MM-II Showed Durable Pain Relief in Global Phase 2b Study
  • Sun Pharma completes acquisition of Concert Pharmaceuticals
  • Sun Pharmaceutical Industries Ltd updates on IT security incident
  • Sun Pharma to acquire stake in Agatsa Software Pvt Ltd and Remidio Innovative Solutions Pvt Ltd
  • Sun Pharmaceutical Industries Ltd declares interim dividend of Rs. 7.50
  • Sun Pharma acquires Disperzyme® and Phlogam® brands to strengthen its anti-inflammatory portfolio
  • Sun Pharma Launches SEZABY™ in the U.S. for Treatment of Neonatal Seizures
  • Sun Pharma to acquire Concert Pharmaceuticals, advancing the Potential Treatment of Alopecia Areata
  • Sun Pharma launches Palbociclib, a novel targeted therapy for advanced breast cancer
  • Sun Pharma is Great Place To Work Certified in India
  • Sun Pharmaceutical Industries Ltd receives warning letter for Halol facility
  • Sun Pharmaceutical Industries Ltd gets import alert for Halol facility
  • SEZABY™ approved by US FDA for the treatment of neonatal seizures
  • Sun Pharma and SPARC enter into a license agreement for commercialization of phenobarbital for injection in the US

Latest Post

  • IREDA makes stellar debut, closes at 87.50% premium to IPO price
  • Foot Locker announces strategic partnership with Metro Brands Ltd and Nykaa Fashion
  • Mahindra Logistics to acquire majority stake in Whizzard
  • R Systems International Ltd honored as one of the 'Value Creators' in Dun & Bradstreet's 'India's Top 500 Value Creators 2023'
  • Ujjivan Small Finance Bank partners with Water.org to offer Water, Sanitation and Hygiene loans


Announcement

To Advertise in our website please e-mail us at advertisement@equitybulls.com
Companies can send their Press Releases to pressrelease@equitybulls.com

Links

  • Home
  • Contact
  • Our Team

Contact

The website is developed and maintained by Chennai Scripts
C-4, Podhigai Flats, Pillayar Koil Street, Nesapakkam
Chennai
Tamil Nadu
India
600078
E-mail: chennaiscripts@gmail.com
Mobile Phone Number: +91-80560-88967
www.chennaiscripts.com

Website Created & Maintained by : Chennai Scripts
Nesapakkam, Chennai - 600 078,
Tamil Nadu, India

Disclaimer Copyright © - 2022